scholarly journals Pharmacogenetics of Immunosuppressive Drugs in Renal Transplantation

10.5772/26325 ◽  
2012 ◽  
Author(s):  
Mara Galiana ◽  
Mara Jos ◽  
Virginia Bos ◽  
Sergio Bea ◽  
Elia Ros ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Immunosuppressive Drugs

scholarly journals Five Yearsʼ Experience in Renal Transplantation with Immunosuppressive Drugs

1968 ◽  
Vol 168 (3) ◽  
pp. 416-435 ◽  
Author(s):  
Joseph E. Murray ◽  
Richard E. Wilson ◽  
Nicholas L. Tilney ◽  
John P. Merrill ◽  
William C. Cooper ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Immunosuppressive Drugs

scholarly journals BK Virus-Associated Nephropathy after Renal Transplantation

Pathogens ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 150
Author(s):  
Yasuhito Funahashi
Keyword(s):  
Renal Transplantation ◽  
Acute Rejection ◽  
Treatment Success ◽  
Simian Virus 40 ◽  
Simian Virus ◽  
Immunosuppressive Drugs ◽  
T Antigen ◽  
Bk Virus ◽  
Screening Tests ◽  
Urinary Cytology

Recent advances in immunosuppressive therapy have reduced the incidence of acute rejection and improved renal transplantation outcomes. Meanwhile, nephropathy caused by BK virus has become an important cause of acute or chronic graft dysfunction. The usual progression of infection begins with BK viruria and progresses to BK viremia, leading to BK virus associated nephropathy. To detect early signs of BK virus proliferation before the development of nephropathy, several screening tests are used including urinary cytology and urinary and plasma PCR. A definitive diagnosis of BK virus associated nephropathy can be achieved only histologically, typically by detecting tubulointerstitial inflammation associated with basophilic intranuclear inclusions in tubular and/or Bowman’s epithelial cells, in addition to immunostaining with anti-Simian virus 40 large T-antigen. Several pathological classifications have been proposed to categorize the severity of the disease to allow treatment strategies to be determined and treatment success to be predicted. Since no specific drugs that directly suppress the proliferation of BKV are available, the main therapeutic approach is the reduction of immunosuppressive drugs. The diagnosis of subsequent acute rejection, the definition of remission, the protocol of resuming immunosuppression, and long-term follow-up remain controversial.

scholarly journals Cost of Treatment After Renal Transplantation in Iran: Should Government Continue Paying for New Expensive Immunosuppressive Drugs?

2013 ◽  
Vol 16 (7) ◽  
pp. A632
Author(s):  
N. Foroutan ◽  
J. Salamzadeh ◽  
A. Foroutan ◽  
H.R. Jamshidi ◽  
H. Rasekh
Keyword(s):  
Renal Transplantation ◽  
Immunosuppressive Drugs ◽  
Cost Of Treatment

STUDY THE DYSLIPIDEMIA AND THE EFFECTIVENESS OF TREATMENT IN PATIENT AFTER RENAL TRANSPLANTATION AT HUE CENTRAL HOSPITAL

2016 ◽  
pp. 58-65
Author(s):  
Tam Vo ◽  
Thi Thuy Linh Nguyen ◽  
Thi Loc Nguyen ◽  
Thanh Minh Nguyen
Keyword(s):  
Kidney Transplantation ◽  
Renal Transplantation ◽  
Hdl Cholesterol ◽  
Immunosuppressive Drugs ◽  
Key Words Renal Transplantation ◽  
Central Hospital ◽  
Related Factors ◽  
Cross Sectional ◽  
Remarkable Effect ◽  
Study Results

Objectives: Survey proportion of dyslipidemia and related factors in after kidney transplantation. Assess the efficancy and side effects of atorvastatin in hyperlipidemia after renal transplantation. Materials and Methods: 43 patients received a kidney transplantation at Hue central Hospital from 06/2013-08/2015.And 26 hyperlipidemia renal transplant recipents was administered with atorvastatin 10mg/day for a period of 2 months base on guideline treatment of NCEC 1991 (National Cholesterol Education Council). A Cross-sectional and prospective study. Results: new-onset dyslipidemia incidence after renal transplantation was 97.7%. Dyslipidemiatreatement base on recommend NCECwas 60.5%.The regimen 1(Neoral+ Cellcept+Prednisolon) and 2 (Prograf+ Cellcept+Prednisolon) have similar effect on change serum lipid before and after transplantation 1 month (p<0.05).On average, serum total cholesterol and serum LDL cholesterol and triglyceride significantly decreased after atorvastatin therapy (p<0.05). Whereas, serum HDL cholesterol also decreased. Renal function, creatinin clearance, transamina, creatinin phosphokinase, CRP, fasting glucose, urine protein without significant changes during the period on atorvastatin. Adverse effects were reported in three cases (2 case increase transamin and 1 case increase creanin phosphokinase). But there was no evidence of myopathy, including myalgia. All events were mild and treatment did not need to be discontinued in any of the case. Elevated transamina and CK spontaneous resolution, even the Atorvastatin is continued. Conclusion: Dyslipidemia met with high rates after transplant and showed no difference in the regimens using immunosuppressive drugs cause this disorder. Treatment with atorvastatin 10 mg / day has remarkable effect of dyslipidemia in patients after renal transplantation. Key words: renal transplantation, immunosuppressive drugs, dyslipidemia.

Sign in / Sign up

Export Citation Format

Share Document